Using imaging data to predict outcomes in ovarian cancer patients
Official title: Radiomic biomarkers for clinical decision support that predict patient outcomes in serous ovarian carcinoma
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11172693 · Data updated 2026-11-12
This study is looking at how regular CT scans can be used to find important clues that help predict how well women with a specific type of ovarian cancer might do after treatment, so doctors can make better choices for their care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 13, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $299,995 |
| NIH project number | 1R56CA279060-01A1 |
| Project ID | NIH-11172693 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with high-grade serous ovarian carcinoma who are undergoing or have undergone first-line chemotherapy.
✕Less likely to help
Patients with other types of ovarian cancer or those who are not receiving treatment may not benefit from this research.
What this research studies
This research investigates how computed tomography (CT) images can be transformed into quantitative data to identify biomarkers that predict survival in women with high-grade serous ovarian carcinoma (HGSOC). By analyzing standard CT scans, the study aims to develop non-invasive tools that can help clinicians make better decisions regarding treatment options. The research will focus on a diverse group of patients to ensure the findings are applicable to a wide population. Ultimately, the goal is to improve patient outcomes by identifying those at risk for adverse effects after initial treatment.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for ovarian cancer patients, improving survival rates and quality of care.
How similar studies have gone: Previous research has shown promise in using imaging biomarkers for cancer prognosis, suggesting that this approach could be effective.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Peres, Lauren Cole — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Peres, Lauren Cole
Related research
Other NIH-funded projects on the same topics.
-
Hippo/YAP pathway in aggressive ovarian cancer
Researchers aim to find out how a cell-control system called Hippo/YAP helps start and drive the most deadly form of ovarian cancer in women.
-
Blocking CDK7 as a new approach for aggressive ovarian cancer
This work explores whether blocking a protein called CDK7 can help treat women with high-grade serous ovarian cancer, especially tumors with CDK7 loss or BRCA-related DNA repair problems.
-
New methods to treat a specific type of ovarian cancer
This study is looking at a tough type of ovarian cancer called high-grade serous tubo-ovarian carcinoma to find out why it often doesn't respond to regular treatments, and it's testing new therapy combinations to help improve outcomes for patients like you.
-
A new CAR T cell therapy targeting ovarian cancer
This study is testing a new type of CAR T cell therapy for women with ovarian cancer that uses special immune cells to better target the cancer and includes a safety feature to help protect patients from side effects.
-
Combining trametinib and navitoclax to treat recurrent ovarian cancer
This study is testing a new combination treatment for women with recurrent ovarian cancer that hasn't responded to standard therapies, aiming to see if it can help improve their outcomes.
-
Targeting a specific protein to treat advanced ovarian cancer
This study is looking at a new way to help people with advanced ovarian cancer by targeting a specific protein that helps cancer cells survive, hoping to make current treatments work better for those who have few options left.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.